From Wikipedia, the free encyclopedia
Chemical compound
Vofopitant
![](https://upload.wikimedia.org/wikipedia/commons/thumb/d/d7/Vofopitant.svg/220px-Vofopitant.svg.png) |
|
Other names | GR205171; GR-205171 |
---|
Routes of administration |
Oral |
---|
ATC code | |
---|
|
(2S,3S)-N-[(2-Methoxy-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl)methyl]-2-phenylpiperidin-3-amine
|
CAS Number | |
---|
PubChem
CID | |
---|
IUPHAR/BPS | |
---|
ChemSpider | |
---|
UNII | |
---|
CompTox Dashboard (
EPA) | |
---|
|
Formula | C21H23F3N6O |
---|
Molar mass | 432.451 g·mol−1 |
---|
3D model (
JSmol) | |
---|
COC1=C(C=C(C=C1)N2C(=NN=N2)C(F)(F)F)CN[C@H]3CCCN[C@H]3C4=CC=CC=C4
|
InChI=1S/C21H23F3N6O/c1-31-18-10-9-16(30-20(21(22,23)24)27-28-29-30)12-15(18)13-26-17-8-5-11-25-19(17)14-6-3-2-4-7-14/h2-4,6-7,9-10,12,17,19,25-26H,5,8,11,13H2,1H3/t17-,19-/m0/s1 Key:XILNRORTJVDYRH-HKUYNNGSSA-N
|
Vofopitant (GR205171) is a drug which acts as an
NK1 receptor
antagonist. It has
antiemetic effects as with other NK1 antagonists,
[1] and also shows
anxiolytic actions in animals.
[2] It was studied for applications such as the treatment of
social phobia and
post-traumatic stress disorder, but did not prove sufficiently effective to be marketed.
[3]
[4]
See also
References
-
^ Gardner CJ, Armour DR, Beattie DT, Gale JD, Hawcock AB, Kilpatrick GJ, et al. (August 1996). "GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity". Regulatory Peptides. 65 (1): 45–53.
doi:
10.1016/0167-0115(96)00071-7.
PMID
8876035.
S2CID
8600542.
-
^ Heldt SA, Davis M, Ratti E, Corsi M, Trist D, Ressler KJ (October 2009).
"Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils". Behavioural Pharmacology. 20 (7): 584–95.
doi:
10.1097/FBP.0b013e32832ec594.
PMC
2946835.
PMID
19675456.
-
^ Furmark T, Appel L, Michelgård A, Wahlstedt K, Ahs F, Zancan S, et al. (July 2005). "Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo". Biological Psychiatry. 58 (2): 132–42.
doi:
10.1016/j.biopsych.2005.03.029.
PMID
16038684.
S2CID
8252615.
-
^ Mathew SJ, Vythilingam M, Murrough JW, Zarate CA, Feder A, Luckenbaugh DA, et al. (March 2011).
"A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial". European Neuropsychopharmacology. 21 (3): 221–9.
doi:
10.1016/j.euroneuro.2010.11.012.
PMC
3478767.
PMID
21194898.